REG - Scancell Hlds - Issue of share options

Scancell HoldingsAnnouncement

21/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240521:nRSU1761Pa&default-theme=true

RNS Number : 1761P  Scancell Holdings Plc  21 May 2024

21 May 2024

 

Scancell Holdings plc

 

("Scancell" or the "Company")

 

Issue of share options

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, announces that on 20 May 2024 it has granted share
options to acquire ordinary shares of 0.1 pence each in the capital of the
Company to Sath Nirmalananthan, CFO and Executive Director.

 

These share options have an exercise price of 10.1pence each, the closing
share price on 20 May 2024, and will vest over three years in three equal
tranches from 29 August 2024 with no vesting criteria other than to remain in
employment. Any unexercised share options which are being granted per the
above will expire at 6pm on 19 May 2034.

 

The Board of Scancell approved the issuance of share option grants to
incentivise and retain directors and staff of the Company. The Board
considered both historical practices and on-going funding requirements in this
regard.

 

Related Party Transaction

The issue of share options to Sath Nirmalananthan are deemed to be a related
party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. The
Company's directors who are independent of the related party transaction,
being all the directors other than Sath Nirmalananthan, consider, having
consulted with the Company's Nominated Adviser, Stifel Nicolaus Europe
Limited, that the terms of the related party transactions are fair and
reasonable insofar as the shareholders of the Company are concerned.

 

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

  1   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name                                                         Sath Nirmalananthan
 2    Reason for the notification
 a)   Position/status                                              Chief Financial Officer and PDMR
 b)   Initial notification/Amendment                               Initial notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                         Scancell Holdings plc
 b)   LEI                                                          2138008RXEG856SNP666
 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  Options to acquire ordinary shares
 b)   Identification Code                                          GB00B63D3314
 c)   Nature of the transaction                                    Grant of options to acquire ordinary shares

 d)   Price(s) and volume(s)                                       1,000,000 share options

                                                                   10.1 pence per share option
 e)   Aggregated information

      - Aggregated volume                                          N/A (single transaction)

      - Price
 f)   Date of the transaction                                      20 May 2024
 g)   Place of the transaction                                     Outside a trading venue

 

 

 For further information, please contact:

 Scancell Holdings plc                                                +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)  +44 (0) 20 7710 7600
 Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking)

 Nick Harland (Corporate Broking)

 WG Partners LLP (Joint Broker)                                       +44(0) 20 3705 9330
 David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby

 Panmure Gordon (UK) Limited (Joint Broker)                           +44 (0) 20 7886 2500
 Freddy Crossley/Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications                                   +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                        scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope(®) and ImmunoBody(®) for vaccines
and GlyMab(®) and AvidiMab(®) for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope(®) and
ImmunoBody(®)) this includes citrullination and homocitrullination of
proteins, whereas its mAb portfolio targets glycans or sugars that are added
onto proteins and / or lipids (GlyMab(®)) or enhances the potency of
antibodies and their ability to directly kill tumour cells (AvidiMab(®)).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKZGZKVGZGDZM